Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment.
The efficacy of the vasoactive compound buflomedil on previously described microcirculation abnormalities observed in sickle cell disease (SCD) was investigated using bulbar conjunctival angioscopy (BCA) and laser doppler flux metering. Eleven sickle cell disease patients at steady state were studied in a double-blind randomized parallel-versus-placebo study (5 patients were given placebo and 6 patients received 600 mg buflomedil per day for 21 days after a washout period of 15 days). The blood flux score measured by BCA improved, indicating reduced entrapment of sickle red blood cells. There was a striking improvement of reactive alterations of vasomotion in the buflomedil group, particularly in postocclusive reactive hyperemia; the half return time was also significantly reduced. These results encourage further studies with buflomedil to investigate long-term effects of this compound in SCD, potential prevention of acute vaso-occlusive events, and degenerative complications.
Bachir
D
D
Centre de la Drépanocytose, Hôpital Henri Mondor, Créteil, France.
Maurel
A
A
Beuzard
Y
Y
Razavian
M
M
Kraiem
A
A
Portos
J L
JL
Galacteros
F
F
D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy* / Q000503:physiopathology; D017546:Angioscopy / Q000379:methods; D004311:Double-Blind Method; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil